Compare ADMA Biologics Inc (ADMA) vs Blackstone Inc (BX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Blackstone Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Blackstone Inc trades at $146.53 (market cap $113.32B). The key difference: Blackstone Inc is far larger — about 52× ADMA Biologics Inc's market cap, and Blackstone Inc pays a 3.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BX | |
|---|---|---|
Market Cap | $2.18B | $113.32B |
Sector | Health | Financials |
52-Week High | $20.38 | $188.68 |
52-Week Low | $7.60 | $102.12 |
Enterprise Value | $2.25B | — |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
